Search results
-
ESMO 2024 – Bristol abandonment overshadows Immatics
ESMO 2024 – Bristol abandonment overshadows Immatics …
- 09/18/2024 - 16:57 -
ESMO 2024 – Torl challenges BioNTech in Claudin6
ESMO 2024 – Torl challenges BioNTech in Claudin6 … Cross-trial comparison of Claudin-6-targeted projects at ESMO 2024 BNT211 TORL-1-23 DS-9606a …
- 09/17/2024 - 12:26 -
ESMO 2024 – Bristol bucks the degrader trend
ESMO 2024 – Bristol bucks the degrader trend …
- 09/17/2024 - 12:26 -
ESMO 2024 – Astellas defends its degrader
ESMO 2024 – Astellas defends its degrader …
- 10/09/2024 - 14:56 -
ESMO 2024 – Scorpion joins Relay in the alpha club
ESMO 2024 – Scorpion joins Relay in the alpha club …
- 09/18/2024 - 21:45 -
ESMO 2024 – J&J eyes Rybrevant colorectal expansion
ESMO 2024 – J&J eyes Rybrevant colorectal expansion …
- 09/16/2024 - 12:28 -
ESMO 2024 – a role for immunotherapy in ovarian cancer
ESMO 2024 – a role for immunotherapy in ovarian cancer …
- 09/15/2024 - 21:18 -
ESMO 2024 – combos could be the way forward for CDK2
ESMO 2024 – combos could be the way forward for CDK2 … Pfizer Blueprint Medicines Presentation ESMO 2024 ESMO 2024 ASCO 2023 ASCO 2024 Study Ph1 …
- 09/15/2024 - 21:18 -
ESMO 2024 – Keytruda/Lenvima leap... up to a point
ESMO 2024 – Keytruda/Lenvima leap... up to a point …
- 09/15/2024 - 15:51 -
ESMO 2024 – Opdualag comes under fire
ESMO 2024 – Opdualag comes under fire …
- 09/15/2024 - 08:35